Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta

Anna Paola Batocchi, M Rotondi, Marcella Caggiula, Giovanni Frisullo, Francesca Odoardi, Viviana Nociti, Carella, Pietro Attilio Tonali, Massimiliano Mirabella

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

83 Citazioni (Scopus)


The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.
Lingua originaleEnglish
pagine (da-a)150-154
Numero di pagine5
RivistaJournal of Neuroimmunology
Stato di pubblicazionePubblicato - 2003


  • Interferon-beta
  • Leptin
  • Multiple Sclerosis


Entra nei temi di ricerca di 'Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta'. Insieme formano una fingerprint unica.

Cita questo